Less Ads, More Data, More Tools Register for FREE

Pin to quick picksBelluscura Regulatory News (BELL)

  • This share is currently suspended. It was suspended at a price of 0.75
  • There is currently no data for BELL

Directorate Change

22 Sep 2025 07:00

RNS Number : 2184A
Belluscura PLC
22 September 2025
 

THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION AS STIPULATED UNDER THE UK VERSION OF THE MARKET ABUSE REGULATION NO 596/2014 WHICH IS PART OF ENGLISH LAW BY VIRTUE OF THE EUROPEAN (WITHDRAWAL) ACT 2018, AS AMENDED. ON PUBLICATION OF THIS ANNOUNCEMENT VIA A REGULATORY INFORMATION SERVICE, THIS INFORMATION IS CONSIDERED TO BE IN THE PUBLIC DOMAIN.

 

22 September 2025

 

 

Belluscura plc

("Belluscura" or the "Company")

 

 

Update regarding Proposed Funding

Board changes

 

 

Belluscura plc (AIM:BELL), a leading medical device developer focused on lightweight and portable oxygen enrichment technology, announces that, further to the statement issued on 12 September 2025, discussions with Omaha Value, Inc. and a connected company called AI Ventures, Inc, regarding the proposed fundraising, have not yet been concluded as anticipated. Discussions have continued, however, with Omaha Value, Inc, AI Ventures, Inc and other potential investors with a view to the refinancing of Belluscura and Belluscura LLC, the Company's main trading subsidiary.

 

As a result, Belluscura LLC has taken steps to enable it to meet its immediate cash requirements.  Whilst the senior management team and those employees responsible for Sales and Shipping have been retained, to ensure the continued fulfilment of customer orders, the employment contracts of 15 of Belluscura LLC's 25 employees in the United States have been terminated.

 

Board changes

 

The Company also announces that Bob Rauker remains CEO of Belluscura LLC but has resigned from the board of Belluscura with immediate effect.

 

Ric Piper, who has been a Director of Belluscura since its AIM flotation in 2021, has also resigned as a non-executive director of Belluscura with immediate effect.

 

 

The ongoing funding discussions mean that the Company is still not yet able to finalise the 2024 Annual Report and Accounts and as a result trading in the Company's shares on AIM remains suspended.

 

 

A further announcement will be made in due course.

 

 

For further information please contact:

 

 

Belluscura plc

Tel: +44 (0)20 3128 8100

Paul Tuson, Chairman

 

SPARK Advisory Partners Limited - Nominated Adviser

Tel: +44 (0)20 3368 3550

Neil Baldwin / Dillon Wall

Dowgate Capital Limited - Joint Broker

Tel: +44 (0)20 3903 7715

Russell Cook / Daniel Ingram

Allenby Capital Limited - Joint Broker

Tel: +44 (0)20 3328 5656

Guy McDougall / Amrit Nahal (Sales and Corporate Broking)

Jeremy Porter / Lauren Wright (Corporate Finance)

MHP - Financial PR & Investor Relations

Tel: +44 (0)20 3128 8100

Katie Hunt / Matthew Taylor

email: Belluscura@mhpgroup.com

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
BOAPKDBDBBKBFCB
Date   Source Headline
13th Jan 202211:05 amRNSSecond Price Monitoring Extn
13th Jan 202211:00 amRNSPrice Monitoring Extension
7th Dec 20217:00 amRNSExercise of Warrants and Total Voting Rights
29th Nov 20217:01 amRNSReimbursement approvals
29th Nov 20217:00 amRNSExercise of Warrants and Total Voting Rights
4th Nov 20217:00 amRNSTrading update
1st Nov 20217:00 amRNSThe Pulse: Healthcare Innovation Breakfast
25th Oct 20217:00 amRNSProduct wins Top Award at US Trade show
18th Oct 20217:00 amRNSNew US Distribution Agreement
8th Oct 20217:00 amRNSDirector/PDMR Shareholding
2nd Sep 20217:00 amRNSNotice of Results
31st Aug 20217:00 amRNSBelluscura supports rationale for wider oxygen use
27th Jul 20217:00 amRNSManufacturing and Distribution Agreement
13th Jul 20217:00 amRNSThird US Distribution Agreement
8th Jul 20217:00 amRNSThe US Centers for Medicare & Medicaid Services
5th Jul 20217:00 amRNSSecond US Distribution Agreement
30th Jun 202112:29 pmRNSResult of AGM
24th Jun 20211:13 pmRNSHolding(s) in Company
23rd Jun 20214:41 pmRNSSecond Price Monitoring Extn
23rd Jun 20214:36 pmRNSPrice Monitoring Extension
23rd Jun 20212:05 pmRNSSecond Price Monitoring Extn
23rd Jun 20212:00 pmRNSPrice Monitoring Extension
23rd Jun 20217:00 amRNSFirst US Distribution Agreement
15th Jun 20217:00 amRNSSenior Management Appointment
9th Jun 20214:15 pmRNSExercise of Warrants
2nd Jun 20217:00 amRNSHolding(s) in Company
28th May 20217:00 amRNSAdmission to trading on AIM; First Day of Dealings

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.